***Meeting program subject to change.
Available Formats: = In Person
= On Demand
7:30–8:30 AM
Frontenac / Petit Frontenac
8:00–8:30 AM
Grand Ballroom
8:15–5:00 PM
Grand Ballroom
Welcome and Keynote Address
8:30–9:30 AM
Grand Ballroom
Elizabeth M. Jaffee, Johns Hopkins University
Cancer Immunotherapy - Where do we Stand Now?
The Failures, Successes and Future of Cancer Immunotherapy
9:30–11:45 AM
Grand Ballroom
Solange Peters, CHUV
Postmortem of Failed Immunotherapy Approaches
Alexandra Snyder, Generate Biomedicines, Inc.
Talk Title to be Announced
Ira Mellman, Parker Institute for Cancer Immunotherapy
The Future of Cancer Immunotherapy
Short Talk(s) Chosen from Abstracts
11:45–12:45 PM
Frontenac / Petit Frontenac
12:30–2:30 PM
Grand Ballroom
Panel Discussion 1: Accelerating Development and Overcoming Regulatory Challenges of Drug Approvals
2:30–4:30 PM
Grand Ballroom
Probing Omics and Big Data to Identify Novel Therapeutic Targets and Biomarkers
5:00–7:00 PM
Grand Ballroom
Arielle Elkrief, Université de Montréal
The Gut Microbiome as a Therapeutic Target in Immuno-oncology
Padmanee Sharma, University of Texas MD Anderson Cancer Center
From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy
Özlem Türeci, BioNTech
Vaccines
Short Talk(s) Chosen from Abstracts
7:30–8:30 AM
Frontenac / Petit Frontenac
8:00–8:30 AM
Grand Ballroom
8:15–5:00 PM
Grand Ballroom
Advances and Challenges of Combination Immunotherapy of Cancer
8:30–11:30 AM
Grand Ballroom
Sandra Demaria, Weill Cornell Medical College
Challenges and Opportunities to Improve Responses to Radiation and Immunotherapy Combinations
Thomas Powles, Barts Cancer Institute
How to Optimally Combine Chemotherapies and Targeted Therapies with Immunotherapy
Thomas Marron, Icahn School of Medicine at Mount Sinai
Neoadjuvant Combination Immunotherapy Approaches: Improving Outcomes and Propelling the Science
James P. Allison, University of Texas MD Anderson Cancer Center
Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanistic Insights Provide New Therapeutic Opportunities
Short Talk(s) Chosen from Abstracts
11:30–12:30 PM
Frontenac / Petit Frontenac
12:30–2:30 PM
Grand Ballroom
1:30–2:30 PM
Grand Ballroom
Panel Discussion 2: “Lessons Learned” from Combination Therapy: What can be Learned from the Failures to Improve Future Successes in Combination Treatment
2:45–4:30 PM
Grand Ballroom
Novel Approaches for Targeting Myeloid and Stromal Cells in the Tumor Microenvironment
5:00–7:00 PM
Grand Ballroom
Shannon J Turley, Genentech, Inc.
Talk Title to be Announced
Karin E. de Visser, Netherlands Cancer Institute
Crosstalk between Eosinophils and Adaptive Immune Cells: A New Avenue for Immune Checkpoint Blockade
Jennifer Guerriero, Brigham and Women's Hospital
Harnessing Macrophages for Anti-Cancer Therapy
Short Talk(s) Chosen from Abstracts
7:30–8:30 AM
Frontenac / Petit Frontenac
Novel Insights into Tumor Recognition by Lymphocytes
8:30–11:30 AM
Grand Ballroom
Tullia C. Bruno, University of Pittsburgh
B Cells
Miriam Merad, Mount Sinai School of Medicine
Novel Insights into the Organization of TLS
E. John Wherry, University of Pennsylvania
Novel T Cell Checkpoints
Carl H June, University of Pennsylvania
Cellular Therapies
Short Talk(s) Chosen from Abstracts
11:30–12:30 PM
Frontenac / Petit Frontenac
Panel: Perspectives: Personalized Medicine & Patient-Centered Strategies
12:45–2:00 PM
Grand Ballroom
Workshop: Novel Platforms to Understand Mechanisms of Action and Resistance
2:30–4:30 PM
Grand Ballroom
Cancer Immunotherapy: Overcoming Resistance
5:00–6:45 PM
Grand Ballroom
Hélène Salmon, Institut Curie
Factors of TME Resistance
Charles Swanton, Francis Crick Institute
Clonal Evolution and Immune Evasion
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Grand Ballroom
